|Drug Name:||Oramorph SR|
|Manufacturer:||Xanodyne pharmaceuticals, inc.|
ORAMORPH SR is supplied as tablets that pose little risk of direct exposure to health care personnel and should be handled and disposed of in accordance with hospital policy.
Patients and their families should be instructed to dispose of ORAMORPH SR tablets, that are no longer needed, down the toilet.ORAMORPH is a trademark of Xanodyne Pharmaceuticals, Inc.© 2006 Xanodyne Pharmaceuticals, Inc.Marketed by:Xanodyne pharmaceuticals, inc.Newport, KY 4107110004432/01Rev.02-2006
Respiratory depression is the chief hazard of all morphine preparations.
Respiratory depression occurs more frequently in the elderly and debilitated patients, as well as in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may dangerously decrease pulmonary ventilation.Morphine should be used with extreme caution in patients who have a decreased respiratory reserve (e.g., emphysema, severe obesity, kyphoscoliosis, or paralysis of the phrenic nerve).ORAMORPH SR should not be given in cases of chronic asthma, upper airway obstruction, or in any other chronic pulmonary disorder without due consideration of the known risk of acute respiratory failure following morphine administration in such patients.